EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease: disease mongering or call to action? (Q53772305)

19 May 2018

title

EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease: disease mongering or call to action? (English)

1 reference

19 May 2018

metabolic dysfunction–associated steatotic liver disease

main subject

1 reference

based on heuristic

inferred from title

non-alcoholic fatty liver

1 reference

1

Elisabetta Bugianesi

1 reference

19 May 2018

publication date

7 April 2016

1 reference

19 May 2018

published in

Diabetologia

1 reference

19 May 2018

volume

59

1 reference

19 May 2018

issue

6

1 reference

19 May 2018

page(s)

1145-1147

1 reference

19 May 2018

Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome

cites work

1 reference

https://api.crossref.org/works/10.1007/S00125-016-3930-7

Epidemiology and natural history of patients with NAFLD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00125-016-3930-7

NAFLD: a multisystem disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00125-016-3930-7

Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00125-016-3930-7

A 360-degree overview of paediatric NAFLD: recent insights.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00125-016-3930-7

Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00125-016-3930-7

Screening for Nonalcoholic Steatohepatitis in Individuals with Type 2 Diabetes: A Cost-Effectiveness Analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00125-016-3930-7

Updated definitions of healthy ranges for serum alanine aminotransferase levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00125-016-3930-7

SAFETY study: alanine aminotransferase cutoff values are set too high for reliable detection of pediatric chronic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00125-016-3930-7

EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00125-016-3930-7

Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27053231

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27053231

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S00125-016-3930-7

1 reference

19 May 2018

1 reference

19 May 2018